source
- Epkinly shows 51% lower risk of progression in frontline DLBCL trial, boosting hopes for expanded approvalNew Phase 3 data from the Epkinly and R-CHOP combination in diffuse large B cell lymphoma showed a 51% reduction in the risk of disease progression or death compared with standard therapy. The stud…
- ArriVent BioPharma's Phase 3 lung cancer trial misses primary endpoint, shares tumbleArriVent BioPharma reported that its investigational EGFR tyrosine kinase inhibitor firmonertinib did not achieve a statistically significant improvement in progression-free survival in the Phase 3…